Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 4 V3 a. M( a7 C' I: w
7 O7 ^& `% Y+ Y0 f$ h9 X" ^; f/ ~1 M) J% ]
Sub-category:+ s, n3 Y( q- H+ @! t* A ?
Molecular Targets 0 u F; q: \( u; K# o7 d
' L5 X9 ~ q q9 v6 ^' I9 w
0 M7 Y: E7 i2 ^$ e% eCategory:
/ k7 b0 t P1 h: }% mTumor Biology
: c3 J d" c! Q: l5 o1 h/ y: ]' S$ v1 B1 o4 L- j: i! E
$ P, w; l: _9 S
Meeting:7 r5 h; [) N; w- t- h
2011 ASCO Annual Meeting , A. F; i+ ]1 `" R6 J
8 |( L/ V: U; R
" A# {! P( M7 a9 cSession Type and Session Title:
1 n* {/ [) ~1 S9 GPoster Discussion Session, Tumor Biology
, a! x+ Y) R0 c) T& ]
/ T( P* q- i0 |, X8 S! ~/ R* \3 y$ F: j/ `3 O
Abstract No:/ R' t N/ N- r _% H3 C
10517 $ ~# [- _" Z( d B) y. ?
3 _) h8 D% d5 \3 s- M/ N
+ X6 ?% B! b& B2 HCitation:. d1 c6 `& v7 s5 C2 \: C0 E3 _, j
J Clin Oncol 29: 2011 (suppl; abstr 10517) - l5 g9 G, k$ l8 H p( y
5 x4 W9 d7 r7 w
# t/ q5 ^' I5 y/ i
Author(s):( y* Z; w2 m/ G, _: {. c
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- X3 O: R' ~2 O" N. L5 i/ b" C+ V! l: H
' k3 L. |* k: p& h$ k
6 V' c' W- M% y, _3 t& o9 ]) ~5 EAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# n, r5 J4 D5 c) Z. ^4 L1 x: }) `9 h0 j* |
Abstract Disclosures! z2 q1 D% @+ b
: A4 _4 p C$ q" t. O$ W' D
Abstract:4 M& X ^. |. |% G2 Y8 \+ o
0 ?% Z8 G, V: v, w1 Z: m+ M% Z2 \
; P, }1 F" j1 ~; ~
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 N: Y+ t2 s7 N% R6 w" {, q
' I. U' @# \. P; a; P; ~# d6 g
& O$ b; ^ }& T+ T. c |
显身卡
